Andrea L Schaffer
Overview
Explore the profile of Andrea L Schaffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Schaffer A, Buckley N, Schumann J, Lim J, Cairns R, Raubenheimer J, et al.
EClinicalMedicine
. 2024 Oct;
77:102858.
PMID: 39416392
Background: Prescribed medicines are commonly used to treat mental health conditions but are also often implicated in suicide death by poisoning. This was a descriptive study quantifying changes in dispensing...
3.
Zoega H, Falster M, Gillies M, Litchfield M, Camacho X, Bruno C, et al.
Pharmacoepidemiol Drug Saf
. 2024 Aug;
33(8):e5887.
PMID: 39145404
Background: The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real-world evidence on prescribed medicine use, effectiveness, safety, costs and cost-effectiveness in Australia. Results:...
4.
Deakin C, Costa J, Brieger D, Lin J, Schaffer A, Kidd M, et al.
Eur Heart J Qual Care Clin Outcomes
. 2024 Aug;
PMID: 39118377
Background: Dual antiplatelet therapy with P2Y12 inhibitors (P2Y12i) and aspirin following acute myocardial infarction (AMI) prevents future ischaemic events. People with atrial fibrillation (AF) also require oral anticoagulants (OAC), increasing...
5.
Schaffer A, Park R, Tazare J, Bhaskaran K, Mackenna B, Denaxas S, et al.
BMJ Open
. 2024 Jul;
14(7):e080600.
PMID: 38960458
Objectives: Long-term sickness absence from employment has negative consequences for the economy and can lead to widened health inequalities. Sick notes (also called 'fit notes') are issued by general practitioners...
6.
Schaffer A, Andrews C, Brown A, Croker R, Hulme W, Nab L, et al.
Lancet Public Health
. 2024 Jun;
9(7):e432-e442.
PMID: 38942555
Background: The COVID-19 pandemic disrupted health-care delivery, including difficulty accessing in-person care, which could have increased the need for strong pharmacological pain relief. Due to the risks associated with overprescribing...
7.
Nab L, Schaffer A, Hulme W, DeVito N, Dillingham I, Wiedemann M, et al.
Pharmacoepidemiol Drug Saf
. 2024 May;
33(6):e5815.
PMID: 38783412
Electronic health records (EHRs) and other administrative health data are increasingly used in research to generate evidence on the effectiveness, safety, and utilisation of medical products and services, and to...
8.
Lin J, Costa J, Pearson S, Buckley N, Brieger D, Schutte A, et al.
J Hypertens
. 2024 May;
42(7):1248-1255.
PMID: 38704239
Background: Adherence to antihypertensives is key for blood pressure control. Most people with hypertension have several comorbidities and require multiple medicines, leading to complex care pathways. Strategies for coordinating medicine...
9.
Brown A, Fisher L, Curtis H, Wiedemann M, Hulme W, Speed V, et al.
Br J Clin Pharmacol
. 2024 Apr;
PMID: 38589944
Aims: The COVID-19 pandemic created unprecedented pressure on healthcare services. This study investigates whether disease-modifying antirheumatic drug (DMARD) safety monitoring was affected during the COVID-19 pandemic. Methods: A population-based cohort...
10.
Wood C, Speed V, Fisher L, Curtis H, Schaffer A, Walker A, et al.
Br J Clin Pharmacol
. 2024 Mar;
90(7):1600-1614.
PMID: 38531661
Aims: The COVID-19 pandemic caused significant disruption to routine activity in primary care. Medication reviews are an important primary care activity ensuring safety and appropriateness of prescribing. A disruption could...